Euroapi (ENXTPA:EAPI) Stock Tracks Revenue Drop And New Net Debt

Euroapi stock has been sliding for weeks, down about 27% over the past month and sitting under €1 before these H1 numbers hit the tape. Today's figures add a fresh twist. Revenue fell to €356.5m and the company booked a net loss of €141.5m, just as net debt swung to €37.9m from a net cash position at the end of 2025.

That is the tension traders are wrestling with. The price hints at deep pessimism already baked in. The earnings headline is a sharp profit squeeze and a fast weakening balance sheet that now has to carry the weight of Euroapi's ongoing transformation plan.

Is Euroapi trading at a genuine deep discount on its 0.1x P/S multiple, or does the DCF gap signal a value trap instead? Compare the data side by side in the valuation analysis for Euroapi.

H1 2026 Earnings Summary

• Revenue, H1 2026 vs. H1 2025: €356.5m vs. €414.5m (decline of 13.5% reported, 11.8% like for like)
• Net Loss, H1 2026 vs. H1 2025: loss of €141.5m vs. loss of €28.5m (loss widened materially)
• Basic EPS, H1 2026 vs. H1 2025: not disclosed for H1 2026 vs. loss of €0.30 per share in H1 2025 (H1 2026 implied to remain loss making)
• Core EBITDA Margin, H1 2026 vs. FY 2026 Guidance: 5.8% in H1 2026 vs. guided approximately 6% for FY 2026 at constant perimeter (margin tracking close to the lower full year target)

Prefer clean, visual charts instead of another wall of Euroapi earnings tables? Get a full picture of how the balance sheet, cash flows and key metrics line up in one visual view through the company report for Euroapi.

Euroapi’s Efficiency Story Meets Messy Execution

Bulls argue Euroapi can reshape its mix toward higher value APIs and contract development and manufacturing work while locking in lower structural costs. The latest half year shows only partial progress. Management points to deliberate pruning of commoditised APIs and divestments, and CDMO sales would have risen about 8% once a single exited large molecule project is stripped out. Commercial phase projects now account for 94% of CDMO revenue, which supports the idea of more visible, higher margin work over time.

On the cost side, the picture is less supportive. Core EBITDA margin sits at 5.8% and full year guidance has been cut to about 6%. Transformation and redundancy charges, impairments and weaker fixed cost absorption have kept reported EBITDA in loss territory. The bullish narrative on efficiency is not broken, but H1 shows it is far from fully proven.

Compare how Euroapi’s shift toward higher value CDMO work lines up against institutional expectations. See the consensus price target analysis for Euroapi to check whether analysts think this transformation is on the right track.

Euroapi Bears See Execution Risks Firmly On Display

The bearish view on Euroapi centres on structurally thin margins, rising costs and a business still tied to pressured small molecule APIs. H1 2026 gives those concerns fresh backing. Core EBITDA margin sits at 5.8% while full year guidance is now cut to about 6%. That is a miss versus the efficiency narrative and shows limited cushion for further shocks such as FX or volume softness.

Fears about small molecule exposure and portfolio pressure also show up clearly. Management booked €33m of impairments linked to weaker mid term demand for certain small molecules and the Brindisi exit. Sales fell as Euroapi pruned commoditised APIs and faced softer demand in corticosteroids and complex molecules. The move from a €68.2m net cash position at end 2025 to €37.9m of net debt by June 2026 adds financial risk just as the transformation spending and non recurring charges stay heavy.

With net cash turning into €37.9m of net debt and transformation costs still heavy, do the current resources genuinely cover Euroapi’s runway? Check the full solvency breakdown in our financial health analysis of Euroapi stock.

Stay Ahead With Simply Wall St

If Euroapi's widening loss, new net debt position and low P/S multiple have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch for a more attractive entry point. Once you hold the stock, use the Portfolio Command Center to cut through market noise and focus on the key developments that matter to your thesis. For longer term context on Euroapi and peers, tap into the collective views and debates inside the Community. Spot potential catalysts and emerging risks early so you can act with confidence and stay ahead of the market.

Seeking Alternatives Beyond Euroapi Stock

Fresh ideas can move before headlines catch up. Scan curated stocks showing early breakout signs, cooling off after sharp runs, or quietly building momentum under the radar. Consider reviewing them while conditions remain favorable.

• Spot potential high quality bargains before momentum takes off by reviewing the curated 248 high quality undervalued stocks while the gap between price and fundamentals still matters.
• Focus on resilient balance sheets and steady execution by using the hand picked list of solid balance sheet and fundamentals stocks (421 results) ahead of broader market attention.
• Track cash generating AI companies that are not just chasing hype by filtering through the focused 65 profitable AI stocks that aren't just burning cash while these stories may still be less widely followed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com